Who are Drug: latanoprost/timolol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Travoprost/timolol therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/drug-latanoprost-timolol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Drug: latanoprost/timolol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug: latanoprost/timolol (Drug: latanoprost/timolol) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog/beta-blocker combination. Area: Ophthalmology.

marketed Prostaglandin analog/beta-blocker combination Prostaglandin F receptor (FP receptor) and beta-adrenergic receptors (β1 and β2) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Drug: latanoprost/timolol (Drug: latanoprost/timolol) — Aristotle University Of Thessaloniki. Latanoprost/timolol is a fixed-dose combination that reduces intraocular pressure through a prostaglandin F analog (latanoprost) that increases uveoscleral outflow and a non-selective beta-blocker (timolol) that decreases aqueous humor production.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Drug: latanoprost/timolol TARGET	Drug: latanoprost/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analog/beta-blocker combination	Prostaglandin F receptor (FP receptor) and beta-adrenergic receptors (β1 and β2)
Travoprost/timolol therapy	Travoprost/timolol therapy	Aristotle University Of Thessaloniki	marketed	Prostaglandin analog/beta-blocker combination	Prostaglandin F receptor (FP receptor) and beta-adrenergic receptors (beta-1 and beta-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog/beta-blocker combination class)

Aristotle University Of Thessaloniki · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Drug: latanoprost/timolol — Competitive Intelligence Brief. https://druglandscape.com/ci/drug-latanoprost-timolol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab